RobertFelixOzolsMD

Physician

Dr. Ozols is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
333 Cottman Ave
Fox Chase Cancer Center
Philadelphia, PA 19111
Phone+1 215-728-6900

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1974 - 1976
University of Rochester School of Medicine and DentistryClass of 1974

PubMed

648 citations
Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
William E. Winter, G. Larry Maxwell, Chunqiao Tian, Jay W. Carlson, Robert F. Ozols
Journal of Clinical Oncology. 2007-08-20
18 citations
Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer.
Robert F. Ozols
Cancer Investigation. 2004-11-10
1534 citations
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncolo...
Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel L. Clarke-Pearson
Journal of Clinical Oncology. 2003-09-01

Spore In Ovarian CancerNational Cancer Institute1999–2006
Core--BiostatisticsNational Cancer Institute1999–2002
Phase I Clinical Trials Of Anticancer AgentsNational Cancer Institute1995–1997
Reversal Of Drug Resistance In Ovarian CancerNational Cancer Institute1990–1997
Detection &Reversal Of Ovarian Cancer Drug ResistanceNational Cancer Institute1990–1992
Symposium On The Biology &Therapy Of Ovarian CancerNational Cancer Institute1990